[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Renovorx Inc (RNXT)

Renovorx Inc (RNXT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 59,572
  • Shares Outstanding, K 45,130
  • Annual Sales, $ 1,120 K
  • Annual Income, $ -11,170 K
  • EBIT $ -14 M
  • EBITDA $ -14 M
  • 60-Month Beta 0.99
  • Price/Sales 53.05
  • Price/Cash Flow N/A
  • Price/Book 6.62

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.05
  • Number of Estimates 2
  • High Estimate $-0.03
  • Low Estimate $-0.07
  • Prior Year $-0.08
  • Growth Rate Est. (year over year) +37.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8401 +57.12%
on 07/24/26
1.5050 -12.29%
on 08/17/26
+0.4424 (+50.41%)
since 07/21/26
3-Month
0.8300 +59.04%
on 07/14/26
1.5050 -12.29%
on 08/17/26
+0.4384 (+49.73%)
since 05/21/26
52-Week
0.7006 +88.41%
on 11/14/25
1.5050 -12.29%
on 08/17/26
+0.4266 (+47.75%)
since 08/21/25

Most Recent Stories

More News
RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

MOUNTAIN VIEW, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies...

RNXT : 1.3200 (unch)
RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment

MOUNTAIN VIEW, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT) , a life-sciences company developing innovative targeted oncology therapies...

RNXT : 1.3200 (unch)
RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth

Increases 2026 Annual Revenue Guidance to a Range of $3.75M to  $4.25M First Treatment Delivered with RenovoCath ® in Patient with Sarcoma in Clinical Setting, Marking Expansion of Device...

RNXT : 1.3200 (unch)
RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer

MOUNTAIN VIEW, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT) , a life-sciences company developing innovative targeted oncology therapies...

RNXT : 1.3200 (unch)
RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors

MOUNTAIN VIEW, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT) , a life sciences company developing innovative targeted oncology therapies...

RNXT : 1.3200 (unch)
RenovoRx to Highlight TAMP™ Platform at JonesTrading Virtual Key Opinion Leader Webinar on the Evolving Pancreatic Cancer Landscape, August 13th

MOUNTAIN VIEW, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) ( Nasdaq: RNXT ), a life sciences company developing innovative targeted oncology therapies...

RNXT : 1.3200 (unch)
RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET

MOUNTAIN VIEW, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT) , a life sciences company developing innovative targeted oncology therapies...

RNXT : 1.3200 (unch)
iAccess Alpha Virtual Best Ideas Summer Investment Conference Begins Today

RALEIGH, NC / ACCESS Newswire / June 23, 2026 / iAccess Alpha's Virtual Best Ideas Summer Investment Conference begins today, bringing together small and micro-cap public companies and investors for a...

ECOR : 10.89 (+3.52%)
BOSC : 4.65 (-0.85%)
MYO : 1.5900 (-8.09%)
AMROF : 0.2350 (+11.90%)
ROC : 4.09 (-2.62%)
EXYN : 2.02 (-8.60%)
ACCS : 4.96 (+0.20%)
SKYX : 1.1500 (unch)
NNBR : 3.84 (+1.69%)
TII : 2.80 (-0.71%)
TI : 5.63 (+0.36%)
MIND : 4.57 (+0.81%)
iAccess Alpha's Virtual Best Ideas Summer Investment Conference June 23–24, 2026

RALEIGH, NC / ACCESS Newswire / June 18, 2026 / iAccess Alpha today announced that it will host its Virtual Best Ideas Summer Investment Conference on June 23-24, 2026, bringing together small and micro-cap...

ECOR : 10.89 (+3.52%)
BOSC : 4.65 (-0.85%)
MYO : 1.5900 (-8.09%)
AMROF : 0.2350 (+11.90%)
ROC : 4.09 (-2.62%)
EXYN : 2.02 (-8.60%)
ACCS : 4.96 (+0.20%)
SKYX : 1.1500 (unch)
NNBR : 3.84 (+1.69%)
TII : 2.80 (-0.71%)
TI.TO : 3.91 (+14.66%)
MIND : 4.57 (+0.81%)
RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer

MOUNTAIN VIEW, Calif., June 11, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or “the Company”) (Nasdaq: RNXT) , a life-sciences company developing innovative targeted oncology therapies...

RNXT : 1.3200 (unch)

Business Summary

RenovoRx Inc. is a biopharmaceutical company. It developed a therapy platform targeting difficult-to-treat tumors. RenovoRx Inc. is headquartered in Silicon Valley, California.

See More

Key Turning Points

3rd Resistance Point 1.4217
2nd Resistance Point 1.3733
1st Resistance Point 1.3467
Last Price 1.3200
1st Support Level 1.2717
2nd Support Level 1.2233
3rd Support Level 1.1967

See More

52-Week High 1.5050
Last Price 1.3200
Fibonacci 61.8% 1.1977
Fibonacci 50% 1.1028
Fibonacci 38.2% 1.0079
52-Week Low 0.7006

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.